Clinical features and death risk factors of pneumocystis jirovecii pneumonia in kidney disease patients with immunosuppressive therapy

• Published in: Zhōnghuá yùfáng-yīxué zázhì Vol. 58; no. 5; p. 673
• Main Authors: Shen, C, Xu, R
• Format: Journal Article
• Language: Chinese
• Published: China 06.05.2024
• Subjects: Acute Kidney Injury - etiology; C-Reactive Protein - analysis; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents - therapeutic use; Kidney Diseases; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors
• ISSN: 0253-9624
• DOI: 10.3760/cma.j.cn112150-20230823-00116

To investigate the clinical features and death risk factors of pneumocystis jirovecii pneumonia (PJP) in kidney disease patients with immunosuppressive patients. A Retrospective case series study was performed in 52 PJP patients with kidney disease who received immunosuppressive therapy in Nephrology or Respiratory department of Peking University First Hospital from January 1, 2006 to August 31, 2021. Patients were divided into survival group (36 cases) and death group (16 cases) according to their clinical outcomes. Univariate analysis was performed to compare the differences of clinical features between the two groups. Multivariate logistic regression model was used to analyze the death risk factors. The results showed that the median serum creatinine was 192.5 (109.8, 293.7) μmol/L, and the incidence of acute kidney injury was 63.5% (33/52). Univariate analysis showed that age ( =1.197, =0.030), C-reactive protein level ( =2.378, =0.022), time from onset to diagnosis ( =6.62, =0.010), PJP severity ( =5.482